Does maternal immunization blunt the effectiveness of pertussis vaccines in infants? A systematic review and modeling study

Michael Briga[a], Elizabeth Goult[a], Tobias S Brett[b,c], Pejman Rohani[b,c], Matthieu Domenech de Cellès[a]

[a]Infectious Disease Epidemiology Group, Max Planck Institute for Infection Biology, Berlin, Germany

[b]Odum School of Ecology, University of Georgia, Athens, GA 30602

[c]Center of Ecology of Infectious Diseases, Athens, GA 30602

Abstract

A key goal of pertussis control is to protect infants too young to be vaccinated, the age group most vulnerable to this highly contagious respiratory infection. In the last decade, maternal immunization has been deployed in many countries, successfully reducing pertussis in this age group. Because of immunological blunting, however, this strategy may erode the effectiveness of primary vaccination at later ages. Here, we systematically reviewed the literature on the relative risk (RR) of pertussis after primary immunization of infants born to vaccinated vs. unvaccinated mothers. The four studies identified had ≤6 years of follow-up and large statistical uncertainty (meta-analysis weighted mean RR: 0.71, 95% CI: 0.38–1.32). To interpret this evidence, we designed a new mathematical model with explicit blunting mechanisms and evaluated maternal immunization's short- and long-term impact on pertussis transmission dynamics. We show that transient dynamics can mask blunting for at least a decade after rolling out maternal immunization. Hence, the current epidemiological evidence may be insufficient to rule out modest reductions in the effectiveness of primary vaccination. Irrespective of this potential collateral cost, we predict that maternal immunization will remain effective at protecting unvaccinated newborns, supporting current public health recommendations.

Introduction

Pertussis is a highly transmissible respiratory infection that is primarily caused by the bacterium *Bordetella pertussis*[1,2]. Pertussis was a leading cause of childhood mortality until intense immunization programs, from the 1940s onwards, reduced pertussis notifications by over 90% in many countries[3,4]. However, in the last couple of decades, pertussis has re-emerged in many populations with high long-term immunization coverage, for reasons which remain highly debated[5].

Newborns are the age group most vulnerable to pertussis. In high-income countries, pertussis-related hospitalization rates in infants under 6 months are between 100 and 100,000 per year[6], and data from the US[7] and Australia[8] show that over 60% of pertussis-associated hospitalizations are under one year old. To reduce the burden of pertussis in vulnerable newborns, since 2012, many countries have introduced maternal immunization—*i.e.*, vaccinating pregnant individuals, usually during the second or third trimester of pregnancy, with a low-dose tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine. In 2015, the World Health Organization (WHO) issued an official recommendation for maternal immunization with acellular vaccines against pertussis (based on studies with acellular primary immunization)[9], and by 2020 maternal immunization against pertussis was recommended in 55 countries[10].

Maternal immunization is highly effective at protecting newborns, with estimates of reductions in the risk of pertussis infection ranging from 70 to 95%[8,11–17]. However, the downstream consequences of maternal immunization, when infants receive their routine pertussis vaccines, are poorly understood. Specifically, there has been long-standing concern regarding potential immunological blunting, *i.e.*, the interference of maternally transferred antibodies with the infant immune response[18–20]. Indeed, several studies and meta-analyses have shown that, after infants received their primary immunization, the antibody concentrations against several pertussis antigens were reduced by 30% to 60% in infants from vaccinated mothers relative to infants from unvaccinated mothers[21–24]. Similarly, the avidity of pertussis antibodies is reduced in infants from vaccinated mothers[25]. Interestingly, the blunting response following maternal pertussis immunization appears to be heterologous, also causing decreased antibody

concentration after infants received a polio vaccine[26] and the blunting response also applies to other vaccines that contain (modified) diphtheria or tetanus toxins as carrier proteins, such as pneumococcus conjugate vaccines [22,26].

While immunological blunting is well documented, because the first maternal immunization programs were implemented in 2012, the long-term consequences of blunting on vaccine effectiveness (VE) and the ensuing epidemiology of pertussis remain difficult to evaluate. Here, we assess the epidemiological evidence for blunting and estimate the long-term consequences of maternal immunization in three steps. First, we perform a systematic review of the literature for estimates of the impact of maternal immunization on the relative risk of pertussis after primary pertussis immunization in infants from vaccinated mothers relative to unvaccinated mothers. Second, we extend a previously validated model of pertussis immunization[4,27] to simulate over several decades the short- and long-term epidemiological impact of maternal immunization with various levels of blunting and maternal immunization coverages on the age-specific time series of pertussis incidence. Third, to identify possible levels of blunting and the consequences of maternal immunization, we match the relative risk estimates obtained from the systematic review with those obtained from the modeling study.

Results

A systematic review of empirical studies on the relative risk of pertussis after maternal and infant primary immunization

We identified 374 peer-reviewed articles and, after removing 146 duplicate records, we screened 228 abstracts for a mention of maternal immunization with either a number of cases, an odds ratio or a relative risk of pertussis and/or effectiveness of a pertussis vaccine (Fig. 1). Based on these criteria, we identified and retrieved 69 articles that might contain information (Table S4).

Our search identified four studies that reported five estimates of the relative risk of pertussis in infants from vaccinated versus unvaccinated mothers and that specified the dose of infant primary immunization (Fig. 1, Fig. 2, Table S1). Two studies were carried

out in the UK, one in Australia, and one in California, US. In all studies, maternal immunization coverage was low right after the implementation of maternal immunization but increased to reach >70% (Table S1). The studies' follow-up times ranged from 2 to 6 years (Table S1). At the first dose of infant primary immunization, these studies showed a weighted mean RR of 0.26 (Fig. 2, 95% CI: 0.11–0.67). At the second dose of infant primary immunization, the RR increased to a weighted mean of 0.73 (Fig. 2, 95% CI: 0.39–1.34) and this was very similar to the weighted mean RR at the third dose of infant primary immunization which had a value of 0.71 (Fig. 2, 95% CI: 0.38–1.32).

The model recapitulates the historical trends of pertussis, with a resurgence caused by a honeymoon effect

To interpret the RR estimates and assess the short- and long-term impact of blunting on pertussis transmission dynamics, we extended an empirically validated model of pertussis epidemiology[4,27], to incorporate maternal immunization and its dual effects of protecting unvaccinated newborns and blunting vaccine effectiveness after infant primary immunization. To assess the historical impact of routine immunization in infants, we first examined the trends in overall incidence and age-specific susceptibility. Infant immunization induced a strong decrease in pertussis incidence but was followed by a rebound with a gradual buildup of susceptible individuals in adult age groups until a new equilibrium—with lower incidence than in the pre-vaccine era—was reached several decades later (Fig. 3 A & B). As previously demonstrated in the US, this resurgence was explained as an "end-of-honeymoon" effect, a predictable consequence of incomplete immunization with imperfect but highly effective vaccines. Hence, our model recapitulated the historical dynamics of pertussis in the US, characterized by a resurgence and shift of infections to adolescent and adult age groups[4].

Transient dynamics after the start of maternal immunization

Second, we examined the impact of maternal immunization, which we introduced 100 years after the rollout of infant immunization, to disentangle the consequences of the two immunization programs. Maternal immunization had the intended effect of decreasing

susceptibility to infection in unvaccinated newborns aged 0–2 months (Fig. 3B). However, after the rollout of maternal immunization, the model predicted a transient phase with lower pertussis incidence, lasting at least 5 years and followed by a rebound (Fig. 4A). In newborns, pertussis incidence was lower after the start of maternal immunization relative to before, but the benefit of maternal immunization was larger in a scenario without blunting than in a scenario with blunting (Fig. 4A). Thus, maternal immunization was predicted to be effective at protecting unvaccinated newborns, with benefits by far outweighing any possible blunting-mediated increases in incidence.

By contrast, in the second age class of infants aged 3–18 months, (*i.e.*, after receipt of the primary pertussis immunization), maternal immunization was followed by a decrease of pertussis incidence, but only when blunting was low (<10%, Fig. 4B). At higher levels of blunting, pertussis incidence was predicted to increase relative to before the start of maternal immunization (Fig. 4B). Irrespective of the simulated blunting level, the second age class also showed a clear transient phase, lasting at least 5 years (Fig. 4B). During this transient phase, pertussis incidence was first predominantly driven by infants from unvaccinated mothers (Fig. 4C), followed later on by incidence in infants from vaccinated mothers, who dominated once incidence had reached equilibrium (Fig. 4D). These dynamics persisted in children up to 5 years of age, but dissipated by age 10 years, after which pertussis incidence remained low and the effects of both maternal immunization and blunting on pertussis incidence were negligible (Fig. S3).

Comparison with empirical estimates suggests that blunting cannot be ruled out

Lastly, we estimated the impact of blunting on the RR of pertussis in vaccinated infants born to mothers vaccinated during pregnancy. In newborns, our simulations show that estimates of the effectiveness of maternal immunization (*i.e.*, based on incidence) have a transient phase in a direction consistent with those deduced from the transient incidence dynamics: the effectiveness of maternal immunization was high at first but decreased with time, and equilibrium values were reached only after a transient phase that lasted at least a decade (Fig. 5A). Hence, ignoring the transient dynamics results in an overestimation of the effectiveness of maternal immunization, an effect most pronounced during the first decade after implementation.

As expected, in the second age class of infants aged 3–18 months, (*i.e.*, after receipt of the primary pertussis immunization), blunting resulted in RR equilibrium values above 1 (*i.e.*, a higher risk of pertussis in infants born to vaccinated mothers relative to unvaccinated mothers), which increased with the input blunting strength. However, these risks were reached only after a transient phase that lasted more than a decade (Fig. 5B). During this transient phase, even in scenarios with blunting, the RR was initially far below 1 and gradually increased after the start of maternal immunization. Hence, ignoring these transient dynamics and assuming that an RR of 1 indicates no blunting may result in overestimating the effectiveness of maternal immunization in both unvaccinated newborns and vaccinated infants (Fig. 5B). It is noteworthy that the transient phase for the estimation of RR (Fig. 5 A & B) is longer than for the incidence (Fig. 4 A & B). This is because RR (and hence VE) are cumulative estimates instead of instantaneous estimates such as incidence (Fig. S4). Interestingly, depending on the contact matrix, the incidence during the transient phase showed oscillating dynamics, which increases the variability between estimates after 3, 6, or even 10 years (Figs. S12, S13), but these oscillations disappeared in the RR estimates (Figs. S14, S15), likely thanks to their cumulative nature. Interestingly, after the transient phase, a scenario without blunting resulted in RRs below 1, due to residual protection from maternal antibodies in infants who were vaccinated but in whom the vaccine did not take. This result suggests that the usual assumption that an RR of 1 indicates no blunting may be too optimistic.

Comparing our model predictions with the results of epidemiological studies, all current empirical RR estimates fell well within the transient phase of our simulations (Fig. 5C). Demographic stochasticity accounted for some of the variability in the predicted RR (Fig. 5B), but observation noise due to small sample sizes was by far the largest source of uncertainty (Fig. 5C). Inspecting the overlap between confidence intervals, all the empirical estimates were consistent with blunting, even though two estimates (in the UK and California) were also consistent with no blunting. Hence, according to our simulations, current empirical studies cannot yet detect the eventual epidemiological consequences of blunting (Fig. 5B), because of the transient RR dynamics following the rollout of maternal immunization. Hence, the model-data comparison suggests that

current empirical RR estimates cannot rule out a modest level of blunting of infant primary immunization (Fig. 5C).

Sensitivity analyses

To assess the robustness of our results, we conducted a range of sensitivity analyses with different hypotheses regarding model parameters, such as the coverage of maternal and infant immunization, the average duration of maternal protection, age-specific contact patterns, the age of primary immunization, and the basic reproduction number). To assess the consequences of non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic, we further simulated scenarios with transient reductions in vaccine coverage and pertussis transmission. In our simulations, variation in these parameters sometimes had a substantial impact on pertussis incidence, e.g., Figs. S7, S9, S11, and S13. However, our conclusions about blunting were robust in all the sensitivity analyses, and the results presented in Figs. S5 to S34 were consistent with those presented in Fig. 4 and Fig. 5.

The sensitivity analyses revealed a few noteworthy results. First, a considerable reduction of the blunting effect on pertussis incidence was predicted when delaying the age at the start of the infant's primary immunization by a few months (Fig. S11, S12). Second, the empirical epidemiological studies with two or three years of monitoring could match scenarios with blunting reducing vaccine effectiveness by up to 50% (Fig. S22). However, such a high level of blunting could be ruled out by the 6-year study in the UK. This indicates the need for larger sample sizes and longer monitoring to reliably estimate vaccine effectiveness and the impact of new immunization programs. Third, consistent with expectation and epidemiological observations, the COVID-19 pandemic was predicted to have a substantial impact on pertussis dynamics, with a decline in incidence followed by a rebound (e.g., Figs. S25 A&B, S27A&B, S29A&B, S31A&B, S34 A-D). However, the temporal dynamics of RR remained consistent in this scenario (Figs. S32, S33, S34 E-H), likely because in our model control measures equally affected infants born from vaccinated or unvaccinated mothers.

Discussion

226

227 In this study, we aimed to review the epidemiological evidence regarding the impact of
228 maternal immunization on the effectiveness of pertussis vaccines in infants. We interpret
229 this evidence using a new mechanistic mathematical model that represented the effect of
230 blunting on pertussis transmission dynamics. Our systematic review identified four
231 observational epidemiological studies, which had a maximum monitoring time of 6 years
232 and were often combined with small sample sizes. Most studies suggested a reduced risk
233 of pertussis after receipt of the first vaccine dose in infants born to mothers immunized
234 during pregnancy. After receipt of the second or third vaccine dose, however, the
235 estimates had large uncertainty, consistent with a range of assumptions about blunting
236 levels. To interpret these empirical estimates, we performed a simulation study using an
237 age-structured model of pertussis transmission. This model predicted that the
238 introduction of maternal immunization was followed by a transient phase lasting at least
239 a decade, during which the blunting effect of maternal antibodies could be
240 underestimated. The model-data comparison suggested that a modest level of blunting
241 could not be ruled out, even though the large uncertainty in empirical estimates
242 prevented a definitive conclusion. Even in the presence of such blunting, however, our
243 model predicted that maternal immunization remained effective at reducing pertussis in
244 unvaccinated newborns. Hence, our results confirm that maternal immunization is an
245 effective strategy to protect this age group, but suggest it may eventually result in an
246 infection-control trade-off with older age groups.
247

248 Unvaccinated newborns are the age group most vulnerable to pertussis, both in terms of
249 infection and hospitalization risks[6,7,8]. Our study suggests that, although blunting may
250 erode the benefits of immunization in infants, maternal immunization is highly effective
251 at protecting unvaccinated newborns. Hence, our results support the decision of many
252 public health authorities to introduce maternal immunization against pertussis, provided
253 that the main control objective is to protect newborns[9,10]. More generally, given the
254 vulnerability of newborns to many pathogens, maternal immunization against other
255 infectious diseases is considered by public health authorities, and the pharmaceutical
256 industry is developing new vaccines for immunization during pregnancy. For example, a
257 maternal vaccine against RSV recently underwent successful phase 3 trial[29] and may soon
258 be rolled out[30]. In addition to the Tdap and RSV vaccines, maternal immunization is

recommended or under development for influenza, COVID-19, polio and several other infections[31–33]. Maternal immunization, therefore, also appears as a promising strategy to protect newborns against these infections, but given that immunological blunting has been documented for many infections[18,34–37], our results suggest the need to monitor its impact on subsequent vaccination of infants carefully.

One of the main takeaways from our review was the large uncertainty around the available empirical estimates, emphasizing the urgent need for more research on blunting. However, if such blunting is confirmed by future evidence, there are ways to mitigate its impact. Immunity in newborns conferred by maternal antibodies against pertussis likely wanes quickly, on a timescale of months, according to our model. Given the fast waning of maternal antibodies and the negative association between the maternal antibody titers and the blunting of infant immune responses[38], delaying infant primary immunization by a few months might greatly reduce the maternal blunting of infant immunization[36]. Pertussis immunization schedules vary greatly between countries, with the age at first immunization of infants typically ranging between two and four months[39], and the current variation in pertussis immunization schedule can significantly impact the effectiveness of pertussis immunization in infants[40]. If maternal blunting occurs, our results suggest that the optimal age at first immunization is governed by a trade-off between vaccinating too early (with the effect of reducing the susceptibility age window in newborns but amplifying the impact of blunting in vaccinated infants) and too late (with the opposite effect). As the costs of infection in unvaccinated newborns likely exceed those in older age groups, the introduction of maternal immunization may thus increase the optimal age at first immunization, in all infants or only in those born to vaccinated mothers. The Dutch public health authorities take an interesting approach: the recommended age for the first dose of primary immunization for children from unvaccinated mothers is two months, while for children from vaccinated mothers the recommendation is to start one month later, at three months[41]. Identifying the optimal pertussis immunization schedule for infants would be helpful for public health authorities, especially given the vast between-country variation in pertussis immunization schedules[39,40,42]. Our new model could thus help future research on optimal vaccine schedules.

After the roll-out of maternal immunization, our model predicted a transient phase lasting approximately a decade, during which the incidence of pertussis—in both unvaccinated newborns and vaccinated infants—initially dropped, but then bounced back and increased to reach a new equilibrium. The duration of this transient phase is consistent with that found in a previous modeling study[43] and may be explained by the time required for the first cohorts of blunted-vaccinated infants (*i.e.*, born to vaccinated mothers) to reach primary school age and its associated high contacts. Thus, reduced transmission from unvaccinated newborns may explain the initial decrease in incidence across age groups, but this benefit gradually wears off as blunted-vaccinated, and therefore less well-protected, children age.

From a practical perspective, the transient phase following maternal immunization has at least two important implications. First, the current individual-based epidemiological studies had ≤6 years of monitoring, which we predict is insufficient to capture the consequences of maternal immunization that can only be detected with at least a decade of data. Second, an RR of 1 is considered the baseline value indicating that maternal immunization does not blunt vaccine effectiveness in infants. In the transient phase, however, our model predicts that the baseline value under a no-blunting scenario starts off close to 0 and gradually increases to an equilibrium just below 1. This equilibrium value results from the residual protection from maternal antibodies, which partially compensates for failures of primary immunization in infants born to vaccinated mothers. These results suggest that the early empirical estimates of vaccine effectiveness may overestimate the benefits of maternal immunization, both for newborns and for infants. A testable prediction of our model, therefore, is that the benefits of maternal immunization estimated in subsequent studies will be lower than those currently reported, both in newborns and after the primary series. More broadly, as reflected in some official guidelines for vaccine impact evaluation[44] and demonstrated for other vaccines such as influenza and streptococcus, biased estimation of vaccine effectiveness because of transient dynamics early after vaccine rollout is likely a more general occurrence.

Epidemiological monitoring studies have, until now, not reported maternal immunization-mediated rebounds in pertussis incidence (e.g.,[45]). However, we believe

that the best way to quantify the clinical and epidemiological impact of blunting is by more precise individual-level estimation of the RR (ideally after the transient phase predicted by our model), instead of monitoring population-level changes in pertussis incidence. This is for several reasons. First, we predict that the rebound a few years after the roll-out of maternal immunization will be small compared to the large reduction immediately after. Hence, detecting an increase in pertussis incidence resulting from maternal immunization may be difficult. Second, many countries have reported pertussis resurgence in the last decades[5], so empirical studies of pertussis incidence may face the challenge of disentangling pre-maternal immunization increases from a post-maternal immunization rebound, which is challenging especially considering the multiannual periodicity of pertussis. The interpretation of trends in pertussis incidence may be further compounded by changes in national immunization schedules (e.g.,[40]) and the impact of NPIs during the COVID-19 pandemic. For the latter, we predict that the RR will remain a more robust metric.

In addition to the monitoring time, other components of the design of current epidemiological studies may affect their interpretation. First, as the mothers' decision to receive Tdap during pregnancy is voluntary and likely related to other socioeconomic factors that will affect—and presumably reduce—their infants' risk of pertussis, the baseline comparability between groups in these observational studies is far from obvious. Hence, estimates of the effectiveness of maternal immunization may have been confounded by healthy user bias; interestingly, the study that controlled most thoroughly for maternal characteristics[16] had large statistical uncertainty around its RR estimates and could not rule out blunting. In addition to this confounding problem, maternal immunization may prevent mothers from transmitting pertussis to their infants, an indirect effect that could lead to underestimating the risk of pertussis and masking the effect of blunting in the group of infants vaccinated and born to vaccinated mothers (as recognized by some investigators[13]). Because of these potential biases, current RR estimates may have been underestimated. Our model does not account for such potential biases and hence our model predictions regarding the level of blunting may be conservative.

357 Our study has several limitations. First, our model was parameterized based on previous
358 estimates in Massachusetts, USA, and may only correctly represent pertussis
359 epidemiology in comparable high-income countries. To adress this limitation, we have
360 performed sensitivity analyses with a range of basic reproduction numbers, and the
361 conclusions were consistent. Second, in the absence of serological correlates of protection
362 for pertussis[46–48], the duration of maternally-derived protection—and in particular how
363 it connects to maternal antibody titers in the infant—is unknown. In our model, this
364 parameter was calibrated to reach empirical estimates of maternal immunization
365 effectiveness in newborns, with an average duration of maternally derived protection at
366 8.7 months resulting in vaccine effectiveness for newborns close to 80%. Even though
367 sensitivity analyses demonstrated that our main results were robust to variations in this
368 parameter, more accurate estimation will be important to inform future models and to
369 predict optimal vaccination schedules. Third, for simplicity, we did not model the direct,
370 protective effect of maternal immunization on mothers—only the indirect effect on their
371 newborns. This direct effect is an additional benefit of maternal immunization, but
372 because in high-income countries the proportion of women giving birth is small relative
373 to the total adult population (2021 range among all EU-member states: 1.1 to 1.8 live
374 births per 1,000 individuals), it is expected to have a minor epidemiological impact.
375 Fourth, in our simulations, maternal immunization coverage was fixed at 70%, while in
376 real-world settings it is often initially low and takes several years to increase to the higher
377 values described in Table S1 (e.g., Fig. 1 in[14]). However, such temporal variations in
378 immunization coverage are expected to increase the duration of the transient phase and
379 would thus reinforce our conclusions about the unreliability of early empirical estimates.
380
381 To conclude, our study shows that maternal immunization is effective at protecting
382 newborns, even when blunting erodes some of its benefits. The degree of blunting, and
383 the extent to which it entails an epidemiological cost in older age groups, can not be
384 known yet, as we predict that the implementation of maternal immunization is followed
385 by a transient phase during which the epidemiological impact of blunting is masked.
386 Hence, current epidemiological studies may be insufficient to rule out blunting or grasp
387 the long-term epidemiological consequences of maternal immunization. Our results,
388 therefore, identify the need for more research to precisely estimate the degree of blunting
389 after primary immunization, if any. More generally, our study supports the use of

390 maternal immunization to reduce pertussis in newborns, but suggests this strategy may
391 be associated with an infection-control trade-off between different age groups.
392
393 **Methods**
394
395 *Systematic review and meta-analysis of empirical studies on the relative risk of pertussis*
396 *after maternal and infant primary immunization*
397
398 We searched the literature on Web of Science, PubMed, and Scopus on August 25, 2023.
399 We used the search terms "maternal immunization AND pertussis AND effectiveness OR
400 maternal vaccination AND pertussis AND effectiveness". In Web of Science, we entered
401 these terms under 'Topic', in PubMed we entered these terms under 'Title/Abstract', and
402 in Scopus under 'Article type, Abstract, Keywords'. In these three searches, we selected
403 the publication dates from January 1, 2012, which is the first complete year with
404 recommended maternal immunization in any country[14], until August 25, 2023. To be
405 included in our review, studies had to provide an estimate of the relative risk (RR) of
406 pertussis in infants having received at least one dose of their primary immunization from
407 vaccinated vs. unvaccinated mothers. We selected only those studies that used
408 laboratory-confirmed diagnosis of pertussis. Because the RR of pertussis varies
409 substantially between doses of infant primary immunization, we selected only studies
410 that were explicit about the number of doses of primary immunization and we excluded
411 those studies that pooled estimates for various doses. For studies that provided more
412 than one estimate per dose, we used all estimates provided. When studies provided
413 estimates with and without known pertussis onset dates, we chose those estimates with
414 known onset dates.
415
416 To estimate the RR per dose of infant primary immunization, we performed the analyses
417 in two ways, which gave consistent results. First, we estimated the weighted means of RR
418 per dose. Second, we performed a meta-regression following[49] and as performed in[50]. In
419 brief, in both analyses, we log-transformed the RR obtained from the studies and
420 weighted the estimates according to the inverse of the 95% CI of the RR estimate. We
421 preferred to use RR rather than the numbers of cases[51] because there are two studies in
422 which RR estimates correct for participants' socio-demographic covariates. The meta-

423 regression allowed the inclusion of all doses (as a factor) into one model and to account
424 for estimates coming from the same studies by having the study identity as a random
425 intercept. To account for the fact that two studies were carried out in the same
426 population, we repeated the meta-regression by including the population as a random
427 intercept, which gave consistent results. We performed the meta-regression in R v. 4.2.0[52]
428 with the function 'brm' from the package 'brms'[53] using flat uninformative priors with
429 100,000 iterations, 20,000 burn-in, and a thinning of 40. Model residuals fulfilled all
430 assumptions as checked with the function 'createDHARMA' of the package 'DHARMa'[54].
431 Meta-analyses usually control the heterogeneity between studies and most importantly
432 for publication bias[49], but given the low number of studies and sample sizes, this was not
433 possible here.
434
435 *Simulation: Model schematic*
436
437 We implemented an age-structured model of pertussis transmission, extending a
438 previous model empirically validated on data from Massachusetts, USA[4,27]. In brief, the
439 model is based on the Susceptible-Exposed-Infected-Recovery (SEIR, Fig. S1) model in
440 which pertussis vaccines can fail by (i) failure in "take" (primary vaccine failure) and (ii)
441 failure in duration (waning of vaccine protection)[55]. Based on immunological evidence
442 showing an immediate reduction in the antibody response to primary vaccination[21,22,36],
443 we assumed that blunting from maternal immunization increased the probability of
444 primary vaccine failure. Previous results in[4] found no evidence for failure in degree (or
445 leakiness, i.e., when vaccine-induced protection is imperfect and vaccinees remain
446 susceptible to infection, but at a lower degree than unvaccinated individuals), and hence
447 we ignored this possibility.
448
449 The model is designed such that we follow individuals grouped according to their
450 immunization history. For each immunization, individuals can go to either of three
451 compartments: one for successful immunization, one for failed immunization, and one for
452 immunization not received (Fig. S1). These three possible paths or compartments start
453 from their mother's immunization status during pregnancy, followed by an infant
454 immunization schedule that resembles that of the empirical studies in Table S1: the
455 infant's primary immunization occurs at the age of three months, and an infant booster

at the age of 1.5 years. Hence, newborns can be born in three possible compartments: from vaccinated mothers whose immunization succeeded, mothers whose immunization failed (i.e., who received the vaccine but whose infant remained unprotected), or unvaccinated mothers. We model maternal immunization by transferring a fraction of newborns to a protected class. Maternal immunization in itself is not modeled; hence our model does not specify at which stage of pregnancy maternal immunization occurs. The assumed high effectiveness of maternal immunization implies that it occurred at a timing consistent with that used in the studies in Table S1 and in the empirical studies of the systematic review, i.e., during the second or third trimester of pregnancy and at least one week before giving birth.

Each of the three compartments is followed by a compartment for successful primary infant immunization (Fig. S1) and a compartment for failed primary infant immunization, thereby becoming susceptible (Fig. S1), or no immunization thereby also becoming susceptible. Following the first booster, these susceptibles become immunized again at an effectiveness of 96%, with a subsequent waning rate of vaccine protection of 0.011 yr^{-1} (Table S3). For simplicity, as in earlier modeling studies[4] , we model the infant primary immunization as one event and we do not consider the gradual effect of multiple vaccine doses.

Model parametrization

Parametrization of the base model

Our model is based on[4], which was fitted to pertussis incidence data from Massachusetts to identify the model parameters that best matched the data. Hence, for the parameters consistent between both models, we used the estimates from[4] (Table S3), but note that the sensitivity analyses explained below and shown in the supplementary information create conditions that represent other populations.

By adding maternal immunization to this model, we also added three new parameters. The first parameter is maternal immunization coverage, for which we use a baseline of 70%, consistent with the empirical estimates a few years after the rollout of maternal immunization (Table S1). The second parameter is the duration of maternally derived

489 immunity, for which, there are no empirical estimates. One proxy is the half-life of
490 maternal antibodies, which ranges between 29 and 36 days[56,57], suggesting that the
491 duration of maternally-derived immunity is short. However, because of the absence of
492 definite correlates of protection[46–48], the correspondence between the waning rate of
493 maternal antibodies and that of maternal immunity is unknown. For example, if both
494 waning rates are assumed equal and without the transfer of new maternal antibodies,
495 e.g., through breastfeeding, according to our model the effectiveness of maternal
496 immunization in the first two months after birth would be close to 50% (Fig. S1). This is
497 in contrast with the estimated effectiveness of maternal immunization in that age class,
498 which ranged from 78% ([15] 95% CI: 48–90) to 93% ([12] 95% CI: 81–97). Thus, in our
499 model, we calibrated the average duration of maternal protection to reach these
500 empirical estimates of vaccine effectiveness and hence we show results with an average
501 duration of 8.7 months (Table S3, Fig. S2). The third parameter is the blunting of infant
502 immune protection, defined as the relative reduction in the effectiveness of the primary
503 series in infants born to vaccinated mothers (compared to infants born to unvaccinated
504 mothers). There are no empirical estimates of the degree of blunting of infant protection
505 following maternal immunization or how changes in IgG titers translate into changes in
506 protection. When infants receive their primary immunization, the antibody
507 concentrations of infants from vaccinated mothers are 30% to 60% lower compared to
508 those from unvaccinated mothers[21,22]. To best match the empirical estimates of the
509 relative risk of pertussis, we chose a decrease in the effectiveness of primary
510 immunization from 0% (i.e., no blunting) to 20%. Formally, the blunting parameter b_1 is
511 modeled as a relative reduction in the initial effectiveness of infant immunization ε,
512 resulting in a blunted effectiveness $\bar{\varepsilon} = \varepsilon(1 - b_1)$.
513
514 Sensitivity analyses
515 We checked the sensitivity of our results to nine model changes:
516 (i) maternal immunization coverage, changed from a baseline value of 70% to
517 50% and to 90% (Fig. S5, S6), which is the range represented in Table S1;
518 (ii) infant immunization coverage, changed from a baseline value of 90% to 70%
519 and 80% (Fig. S7, S8);
520 (iii) the average duration of maternal protection changed from a baseline value of
521 8.7 months to 4 months and 1 year (Fig. S9, S10);

522 (iv) the start of primary immunization, changed from a baseline value of 3 months
523 to 2, 4, and 9 months (Fig. S11, S12);
524 (v) different social contact matrices, with that of the UK as baseline (in Figs. 4 and
525 5) and changed to those in 7 other European countries as described in[58,59] (Fig.
526 S13-S18);
527 (vi) starting the maternal immunization program 60 years after the rollout of
528 primary immunization, instead of 100 years. This reflects an introduction of
529 maternal immunization during a honeymoon-mediated pertussis resurgence,
530 as was the case in many countries (Fig. S19, S20);
531 (vii) blunting the effectiveness of the infant primary immunization up to 60% (Fig.
532 S21, S22), instead of the baseline range of 0% to 20%;
533 (viii) ±50% variations in the basic reproduction number, to model different
534 transmission levels in a range of populations (Fig. S23, S24);
535 (ix) the impact of the COVID-19 pandemic, modeled as 3- to 9-month period
536 associated with lower vaccine coverage (20% reduction) and lower
537 transmission (20%, 50%, or 70% reduction, as a result of social distancing
538 measures, Fig. S25-S34). This sensitivity analysis is motivated by the
539 observation that COVID-19-associated social distancing measures
540 substantially decreased pertussis incidence[60,61]. To model NPIs during the
541 COVID-19 pandemic, we followed the approach from a previous study which
542 reduced the transmission between 20% and 70% for a duration of 3 months
543 and 9 months[62]. We obtained estimates of the changes in immunization
544 coverage during the COVID-19 pandemic from three empirical studies[63–65]. In
545 our model, we introduced these changes 8 years after the rollout of the
546 maternal immunization program because that matches the 8-year lag between
547 the first maternal immunization programs and the COVID-19 NPIs in most
548 countries.
549
550 *Estimation of relative risk of infection following maternal immunization*
551
552 To connect the model outputs with the empirical estimates of relative risk (RR)[13,14,16,17],
553 we calculated the risk of contracting pertussis in infants born to vaccinated mothers
554 relative to that of infants born to unvaccinated mothers using the same approach as

in[13,17]. These studies used the screening method following[66], in which the RR is estimated as:

$$RR = \frac{PCV}{(1 - PCV)} \cdot \frac{(1 - PPV)}{PPV}$$

where PCV (proportion of cases vaccinated) is the proportion of cases in vaccinated infants born to vaccinated mothers among all cases in infants vaccinated, and PPV is the proportion of the population vaccinated, here equal to the vaccine coverage of maternal immunization. We validated the RR estimates of the simulations by setting the half-life of maternally derived protection to infinity, which resulted in a RR of 0.05 in newborns and matched the initial 95% effectiveness of maternal immunization against pertussis in unvaccinated newborns fixed in the simulations (Fig. S2, Table S3). Hence, while the screening method may have several limitations in real-world settings[67], it provided reliable estimates of vaccine effectiveness in the context of our model.

Numerical implementation

We represented the process model as a continuous-time Markov process, approximated via the tau-leap algorithm[68] with a fixed time step of 1 day. To compare the model outputs to empirical estimates, we also added an observation model for the RR. This was done by sampling the number of vaccinated cases born to vaccinated mothers from a Binomial distribution with probability PCV and size equal to the number of cases described in the empirical studies at the third dose (Table S1). The model was implemented and simulated using the 'pomp' package v. 4.4.3.0[69], operating in R v. 4.2.0[52].

References

1. Kilgore, P. E., Salim, A. M., Zervos, M. J. & Schmitt, H. J. Pertussis: Microbiology, Disease, Treatment, and Prevention. *Clin. Microbiol. Rev.* **29**, 449–486 (2016).
2. Rohani, P. & Scarpino, S. V. *Pertussis: Epidemiology, Immunology & Evolution*. (Oxford University Press, Oxford, 2019).
3. Amirthalingam, G., Gupta, S. & Campbell, H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. *Euro Surveill.* **18**, ii=20587 (2013).
4. Domenech de Cellès, M., Magpantay, F. M. G., King, A. A. & Rohani, P. The impact of past

586 vaccination coverage and immunity on pertussis resurgence. *Sci. Transl. Med.* **10**, eaaj1748
587 (2018).
588 5. Domenech de Cellès, M., Magpantay, F. M. G., King, A. A. & Rohani, P. The pertussis enigma:
589 reconciling epidemiology, immunology and evolution. *Proc. Biol. Sci. B* **283**, 20152309
590 (2016).
591 6. Kandeil, W. *et al.* A systematic review of the burden of pertussis disease in infants and the
592 effectiveness of maternal immunization against pertussis. *Expert Rev. Vaccines* **19**, 621–638
593 (2020).
594 7. Mbayei, S. A. *et al.* Severe Pertussis Infections in the United States, 2011–2015. *Clin. Infect.*
595 *Dis.* **69**, 218–226 (2019).
596 8. Quinn, H. E. *et al.* Pertussis disease and antenatal vaccine effectiveness in Australian
597 children. *Pediatr. Infect. Dis. J.* **41**, 180–185 (2022).
598 9. World Health Organization. Pertussis vaccines: WHO position paper – August 2015. (2015).
599 10. Abu-Raya, B. *et al.* Global perspectives on immunization during pregnancy and priorities for
600 future research and development: an international consensus statement. *Front. Immunol.*
601 **11**, 1282 (2020).
602 11. Amirthalingam, G. *et al.* Effectiveness of maternal pertussis vaccination in England: an
603 observational study. *Lancet* **384**, 1521–1528 (2014).
604 12. Dabrera, G. *et al.* A case-control study to estimate the effectiveness of maternal pertussis
605 vaccination in protecting newborn infants in England and Wales, 2012–2013. *Clin. Infect.*
606 *Dis.* **60**, 333–337 (2015).
607 13. Amirthalingam, G. *et al.* Sustained effectiveness of the maternal pertussis immunization
608 program in England 3 years following introduction. *Clin. Infect. Dis.* **63**, S236–S243 (2016).
609 14. Baxter, R., Bartlett, J., Fireman, B., Lewis, E. & Klein, N. P. Effectiveness of vaccination during
610 pregnancy to prevent infant pertussis. *Pediatrics* **139**, e20164091 (2017).
611 15. Skoff, T. H. *et al.* Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis
612 Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control

613 Evaluation. *Clin. Infect. Dis.* **65**, 1977–1983 (2017).
614 16. Rowe, S. L. *et al.* Maternal vaccination and infant influenza and pertussis. *Pediatrics* **148**,
615 e2021051076 (2021).
616 17. Amirthalingam, G. *et al.* Optimization of Timing of Maternal Pertussis Immunization From 6
617 Years of Postimplementation Surveillance Data in England. *Clin. Infect. Dis.* **8**, e1129–e1139
618 (2023).
619 18. Albrecht, P., A, E. F., Saltzman, E. J. & S, K. Persistence of maternal antibody in infants
620 beyond 12 months: mechanism of measles vaccine failure. *J. Pediatr.* **91**, 715–717 (1977).
621 19. Bento, A. I., King, A. A. & Rohani, P. Maternal pertussis immunisation: clinical gains and
622 epidemiological legacy. *Euro Surveill.* **22**, 30510 (2017).
623 20. Leuridan, E. Pertussis vaccination in pregnancy: State of the art. *Vaccine* **35**, 4453–4456
624 (2017).
625 21. Barug, D. *et al.* Maternal pertussis vaccination and its effects on the immune response of
626 infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised
627 controlled trial. *Lancet Infect. Dis.* **19**, 392–401 (2019).
628 22. Abu-Raya, B. *et al.* The effect of Tetanus-Diphtheria-Acellular-Pertussis immunization
629 during pregnancy on infant antibody responses: individual-participant data meta-analysis.
630 *Front. Immunol.* **12**, 689394 (2021).
631 23. Jones, C. E. *et al.* A phase IV, multi-centre, randomized clinical trial comparing two
632 pertussis-containing vaccines in pregnant women in England and vaccine responses in
633 their infants. *BMC Med.* **19**, 138 (2021).
634 24. Sapuan, S. *et al.* An observational, cohort, multi-centre, open label phase IV extension study
635 comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were
636 randomised to one of two pertussis-containing vaccines or received no pertussis-
637 containing vaccine in pregnancy in England. *Vaccine* **40**, 7050–7056 (2022).
638 25. Caboré, R. N. *et al.* Influence of maternal vaccination against diphtheria, tetanus, and
639 pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in

640 Belgium. *Virulence* **8**, 1245–1254 (2017).
641 26. Zimmermann, P. *et al.* The effect of maternal immunisation during pregnancy on infant
642 vaccine responses. *EClinicalMedicine* **13**, 21–30 (2019).
643 27. Domenech de Cellès, M., Rohani, P. & King, A. A. Duration of Immunity and Effectiveness of
644 Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. *JAMA Pediatr.* **173**, 588–594
645 (2019).
646 28. McLean, A. R. & Anderson, R. M. Measles in developing countries Part I. Epidemiological
647 parameters and patterns. *Epidemiol. Infect.* **100**, 111–133 (1988).
648 29. Kampmann, B. *et al.* Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in
649 Infants. *N. Engl. J. Med.* **388**, 1451–1464 (2023).
650 30. Venkatesan, P. First RSV vaccine approvals. *Lancet Microbe* **4**, e577 (2023).
651 31. Omer, S. B. Maternal Immunization. *N. Engl. J. Med.* **376**, 1256–1267 (2017).
652 32. Halasa, N. B. *et al.* Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine
653 During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months
654 - 17 States, July 2021-January 2022. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 264–270 (2022).
655 33. Etti, M. *et al.* Maternal vaccination: a review of current evidence and recommendations. *Am.*
656 *J. Obstet. Gynecol.* **226**, 459–474 (2022).
657 34. Gans, H. A. *et al.* Deficiency of the Humoral Immune Response to Measles Vaccine in Infants
658 Immunized at Age 6 Months. *JAMA* **280**, 527–532 (1998).
659 35. Mawa, P. A. *et al.* The impact of maternal infection with Mycobacterium tuberculosis on the
660 infant response to bacille Calmette–Guérin immunization. *Philos. Trans. R. Soc. Lond. B Biol.*
661 *Sci.* **3017**, 20140137 (2015).
662 36. Voysey, M. *et al.* The influence of maternally derived antibody and infant age at vaccination
663 on infant vaccine responses: an individual participant meta-analysis. *JAMA Pediatr.* **17**,
664 637–646 (2017).
665 37. Grassly, N. C. *et al.* Effect of maternal immunisation with multivalent vaccines containing
666 inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-

667 centre randomised trial. *Vaccine* **41**, 1299–1302 (2023).
668 38. Abu-Raya, B. *et al.* Factors affecting antibody responses to immunizations in infants born to
669 women immunized against pertussis in pregnancy and unimmunized women: Individual-
670 Participant Data Meta-analysis. *Vaccine* **39**, 6545–6552 (2021).
671 39. Perkins, T. A. & Tran, Q. M. Timing is everything when it comes to pertussis vaccination.
672 *Lancet Infect. Dis.* **22**, 158–159 (2022).
673 40. Paireau, J. *et al.* Impact of vaccine schedule change on pertussis epidemiology in France: a
674 modelling and serological study. *Lancet Infect. Dis.* **22**, 265–273 (2022).
675 41. Rijksinstituut_Voor_Volksgezondheid_en_Milieu. Rijksinstituut voor Volksgezondheid en
676 Milieu. *Dutch National Immunisation Programme*
677 https://rijksvaccinatieprogramma.nl/english.
678 42. Riolo, M. A. & Rohani, P. Combating pertussis resurgence: One booster vaccination schedule
679 does not fit all. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E472–E477 (2015).
680 43. Bento, A. I. & Rohani, P. Forecasting Epidemiological Consequences of Maternal
681 Immunization. *Clin. Infect. Dis.* **63**, S205–S212 (2016).
682 44. World Health Organization. *Measuring impact of streptococcus pneumoniae and*
683 *haemophilus influenzae type b conjugate vaccination*. (2012).
684 45. Skoff, T. H., Deng, L., Bozio, C. H. & Hariri, S. US Infant Pertussis Incidence Trends Before and
685 After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis Vaccine. *JAMA*
686 *Pediatr.* In press (2023).
687 46. Van Rie, A., Wendelboe, A. M. & Englund, J. A. Role of maternal pertussis antibodies in
688 infants. *Pediatr. Infect. Dis. J.* **24**, S62–S65 (2005).
689 47. Diavatopoulos, D. A. *et al.* PERISCOPE: road towards effective control of pertussis. *Lancet*
690 *Infect. Dis.* **19**, e179–e186 (2019).
691 48. Chen, Z. *et al.* Evaluation of serum anti-pertussis toxin IgA antibodies for the diagnosis of
692 Bordetella pertussis infection in young children. *J. Infect. Public Health* **16**, 1167–1173
693 (2023).

694 49. Nakagawa, S. & Santos, E. S. A. Methodological issues and advances in biological meta-
695 analysis. *Evol. Ecol.* **26**, 1253–1274 (2012).
696 50. Kärkkäinen, T., Briga, M., Laaksonen, T. & Stier, A. Within-individual repeatability in
697 telomere length: A meta-analysis in nonmammalian vertebrates. *Mol. Ecol.* **31**, 6339–6359
698 (2022).
699 51. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J. Stat. Softw.* **36**,
700 1–48 (2010).
701 52. R Core Team. *R: A Language and Environment for Statistical Computing*. https://www.R-
702 project.org/ (2022).
703 53. Bürkner, P.-C. brms: An R Package for Bayesian Multilevel Models Using Stan. *J. Stat. Softw.*
704 **80**, 1–28 (2017).
705 54. Hartig, F. DHARMa: Residual Diagnostics for Hierarchical (Multi-Level / Mixed) Regression
706 Models. R package version 0.4.6. http://florianhartig.github.io/DHARMa/ (2022).
707 55. McLean, A. R. & Blower, S. M. Imperfect vaccines and herd immunity to HIV. *Proc. R Soc B*
708 *Biol. Sci.* **253**, 9–13 (1993).
709 56. Healy, C. M. *et al.* Kinetics of maternal pertussis-specific antibodies in infants of mothers
710 vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy.
711 *Vaccine* **38**, 5955–5961 (2020).
712 57. Oguti, B. *et al.* The half-life of maternal transplacental antibodies against diphtheria,
713 tetanus, and pertussis in infants: an individual participant data meta-analysis. *Vaccine* **40**,
714 450–458 (2022).
715 58. Mossong, J. *et al.* Social contacts and mixing patterns relevant to the spread of infectious
716 diseases. *PLoS Med.* **5**, e74 (2008).
717 59. Béraud, G. *et al.* The French Connection: The First Large Population-Based Contact Survey
718 in France Relevant for the Spread of Infectious Diseases. *PLoS One* **10**, e0133203 (2015).
719 60. Tessier, E. *et al.* Impact of the COVID-19 pandemic on Bordetella pertussis infections in
720 England. *BMC Public Health* **22**, 405 (2022).

721 61. Reicherz, F., Golding, L., Lavoie, P. M. & Abu-Raya, B. Decay of anti-Bordetella pertussis
722 antibodies in women of childbearing age following COVID-19 non-pharmaceutical
723 measures. *Vaccine* **40**, 3746–3751 (2022).
724 62. Brett, T. S. & Rohani, P. Transmission dynamics reveal the impracticality of COVID-19 herd
725 immunity strategies. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 25897–25903 (2020).
726 63. Causey, K. *et al.* Estimating global and regional disruptions to routine childhood vaccine
727 coverage during the COVID-19 pandemic in 2020: a modelling study. *Lancet* **398**, 522–534
728 (2021).
729 64. Kim, S., Headley, T. Y. & Tozan, Y. Universal healthcare coverage and health service delivery
730 before and during the COVID-19 pandemic: A difference-in-difference study of childhood
731 immunization coverage from 195 countries. *PLoS Med.* **19**, e1004060 (2022).
732 65. Lai, X. *et al.* Estimating global and regional between-country inequality in routine childhood
733 vaccine coverage in 195 countries and territories from 2019 to 2021: a longitudinal study.
734 *EClinicalMedicine* **60**, 102042 (2023).
735 66. Farrington, C. P. Estimation of vaccine effectiveness using the screening method. *Int. J.*
736 *Epidemiol.* **22**, 742–746 (1993).
737 67. Minodier, L. *et al.* Influenza vaccine effectiveness: best practice and current limitations of
738 the screening method and their implications for the clinic. *Expert Rev. Vaccines* **13**, 1039–
739 1048 (2014).
740 68. He, D., Ionides, E. L. & King, A. A. Plug-and-play inference for disease dynamics: measles in
741 large and small populations as a case study. *J. R. Soc. Interface* **7**, 271–283 (2010).
742 69. King, A. A., Nguyen, D. & Ionides, E. L. Statistical Inference for Partially Observed Markov
743 Processes via the R Package pomp. *J. Stat. Softw.* **69**, 1–43 (2016).
744 70. Page, M. J. *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic
745 reviews. *BMJ* **372**, n71 (2021).

746

Acknowledgements

We thank the useful discussions and feedback from Andrew Tredennick (University of Georgia, USA), Christian Gunning (University of Georgia, USA), Denis Macina (Sanofi Pasteur, France), Laurent Coudeville (Sanofi Pasteur, France), and Edward Thommes (Sanofi Pasteur, Canada).

Data Reproducibility

All R scripts are currently available at: https://drive.google.com/drive/folders/1-tT3XaPYwPbviXe1OB7_hvN8SSYe9HYJ, and will be made freely available upon publication via Edmond, the Open Data Repository of the Max Planck Society.

Potential conflict of interests

Prof. Pejman Rohani received funding from Sanofi France for another separate project.



Fig. 1 Prisma flow chart, following[70], of the literature search for empirical estimates of the relative risk (RR) of contracting pertussis following maternal immunization in children who had received at least one dose of infant primary immunization.



765

766 Fig. 2 Overview of the results from empirical epidemiologic studies of the relative risk of
767 contracting pertussis after 1–3 vaccine doses for primary immunization in infants from
768 vaccinated mothers relative to those of unvaccinated mothers during infant primary
769 immunization. The literature search protocol is shown in Fig. 1, and the data are available
770 in Table S1. The two lines for the UK 3-year study represent two estimates of maternal
771 immunization coverage. References: Australia 2 yrs[16], California 6 yrs[14], UK 3 yrs[13], and
772 UK 6 yrs[17].



Fig. 3 Illustration of honeymoon effects and transient susceptible dynamics following the start of infant immunization (vertical dashed line at time = 0 years) and maternal immunization without blunting (vertical dashed line at time = 100 years) showing (A) pertussis incidence and (B) the fraction susceptible for each age class from one stochastic simulation.



Fig. 4 Model predictions of the consequences of maternal immunization and blunting for pertussis incidence in (A) unvaccinated newborns (aged 0–2 mo) and (B) vaccinated infants (aged 3–18 mo, after receipt of primary immunization). For this age class, during the transient phase after maternal immunization, pertussis incidence is at first mostly driven by (C) infants from unvaccinated mothers until (D) pertussis incidence is most abundant in infants from vaccinated mothers. Panel (D) is consistent with the PCV-term in the RR equation (see methods, [66]). Solid lines show the median incidence of 100 simulations and shaded areas represent the 95% CI. Pertussis incidence before the start of the maternal immunization program is shown as a control, and variation in incidence between simulations is the result of demographic stochasticity. In this figure, all immunization coverages were set at 70%, which is close to the mean observed values in empirical studies (e.g., Table S1). Note the different *y*-axis between panels.


A
0–2 months
Relative risk of pertussis
0.25
0.20
0.15
0.10
0.05
0.00
1
5
10
25
50
75
Time since start maternal immunization program (years)
Simulated blunting
0%
10%
20%
B
3–18 months
Relative risk of pertussis
3
2
1
0
1
5
10
25
50
75
Time since start maternal immunization program (years)
C
3–18 months
Relative risk of pertussis
6
4
2
0
n=11
n=14
n=21
n=169
2
3
6
6
Time since start maternal immunization program (years)
Study
Australia
California
UK
UK
Simulated blunting
0%
10%
20%

792

Fig. 5 Temporal dynamics of the risk of contracting pertussis in (A) unvaccinated newborns and (B, C) vaccinated infants from vaccinated mothers relative to those of unvaccinated mothers.. (A, B) Solid lines show the median RR of 100 simulations and shaded areas show 95% CI resulting from demographic stochasticity across simulations. (C) Comparison between the results from model simulations (gradient red diamonds) and the empirical studies (colored dots). In simulations, vertical lines show 95% CI due to demographic stochasticity and observation uncertainty, resulting from the partial sampling of the population with sample sizes matching those from empirical studies in Fig. 2 (Table S1).